Sanofi Consumer Healthcare India Limited (BSE: 544250 | NSE: SANOFICONR) has posted a robust financial performance for the second quarter of 2025, registering a 28% year-on-year increase in revenue to ₹2,209 million. The company also reported a 21% rise in profit after tax (PAT), which stood at ₹607 million. The growth was primarily fuelled by the commencement of export operations, successful product launches, and the relaunch of key brands. Sales grew by 27.5% quarter-on-quarter and 27.6% compared to the same quarter last year.
Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said: “Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers.”
Key highlights of the quarter include the relaunch of Depura 60k and Combiflam Suspension, both of which were voluntarily recalled last year, along with the introduction of Allegra D in the allergy segment. Legacy brands like Avil and Depura continue to maintain consumer trust and contribute to long-term relevance in their categories.
In Kolkata, Sanofi Consumer Healthcare continues to witness steady growth, particularly driven by strong demand for its legacy brands like Avil and Depura. Retailers report increased consumer interest in newly relaunched products such as Combiflam Suspension and Depura 60k, which have regained shelf space and confidence after last year’s recall. The recent launch of Allegra D has also received a positive response in metro pharmacies and organized retail chains across the city.
